Tele: 561.316.3330
Breaking Medical Device News

Tuesday, October 19, 2021

HomeCeloNova Announces Positive Clinical Results of eCOBRA Study at EuroPCR 2018

CeloNova Announces Positive Clinical Results of eCOBRA Study at EuroPCR 2018

CeloNova BioSciences, Inc. (CeloNova), a global medical device company that offers a family of innovative products based upon its proprietary PolyzeneTM-F nanocoating technology, today announced 1-year clinical trial results from the eCOBRA post-market study of the company’s COBRA PzFTM NanoCoated Coronary Stent (NCS) System.

The clinical trial results demonstrated 4.3% target lesion revascularization, 0.3% late stent thrombosis and 8.6% major adverse cardiovascular events in patients at high risk for bleeding and thrombosis. The average age of patients was 76 years old. Approximately 30% of patients studied were on oral anticoagulant (OAC) therapy, and 48% had Non–ST- segment elevation myocardial infarction (NSTEMI) or ST-Elevation myocardial infarction (STEMI) at clinical presentation.

“The data from this trial provides further evidence that COBRA PzF NCS is a safe and effective treatment, particularly in complex patients with heart disease,” said Luc Maillard, MD, principal investigator for the eCOBRA trial and Director of the Department of Cardiology, Clinique Axium, Aix-en-Provence, France. “Being able to provide an effective therapy that meets the needs of patients who are at higher risk of bleeding is of great clinical value.”

eCOBRA is a prospective, consecutively enrolled, observational, multi-center, all-comers study comprised of 1,026 patients across 17 centers, including patients with stable angina and acute coronary syndrome. The study is designed to evaluate the safety and effectiveness of COBRA PzF NCS in patients undergoing treatment of de novo coronary lesions where a drug-eluting stent (DES) is typically not indicated.

“I am very excited by eCOBRA’s outstanding results as they support COBRA PzF NCS’ ability to offer an individualized treatment option for a greatly underserved population of high-risk patients,” stated Jason Cone, CEO of CeloNova. “We look forward to further exploring its safety and efficacy in our first-of-its- kind COBRA REDUCE trial with ultra-short, 14-day DAPT.”

The COBRA REDUCE trial is the world’s first and only randomized control trial to assess 14-day DAPT after percutaneous coronary intervention (PCI) as compared to FDA-approved DES with 3 or 6-months of DAPT in patients on oral anticoagulant. For more information about this ongoing global clinical trial, please visit

Medical Device News Magazine
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected


Don't Miss

Adam S. Epstein New CEO of AliMed, Inc.

In his prior role as Chief Commercial Officer, Epstein directed all customer-facing, demand generation and product development activities. Under his new leadership, AliMed will continue to build a robust portfolio of contracted positions with major, national GPO’s, IDN’s, and Distribution partners to drive sales growth.

Tony Collins Appointed CFO of Xenter

“Xenter is building a platform for medical innovations that is transformational. The only way we can achieve our objectives is if we have great leaders like Tony Collins leading our company,” stated Richard J. Linder, Founder, Chairman & CEO of Xenter, Inc. “Tony brings incredible depth and experience to his new role as Chief Financial Officer.

Scott Sexton Appointed President at FIGUR8

"Scott brings to FIGUR8 30 years of workers' compensation, casualty, disability, and commercial health experience, most recently serving as a market leader for CorVel's national carrier practice sales team," said Nan-Wei Gong, CEO, and co-founder of FIGUR8.

Insulet Announces Board of Director Changes with Appointment of Luciana Borio, M.D. and Retirement of Sally W. Crawford

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced...

Ganymed Robotics Awarded a €2.5M Grant from the EC through the EIC Accelerator Program

Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.

Global Healthcare Exchange Announces Acquisition of Explorer Surgical

Explorer Surgical will operate as a wholly-owned subsidiary of GHX.

By using this website you agree to accept Medical Device News Magazine Privacy Policy